# MEN Syndromes Pathology > MEN syndromes pathology for MBBS Pathology: MEN1 menin 3 Ps, MEN2A and 2B RET, prophylactic thyroidectomy timing and pheochromocytoma-first rule. - Canonical URL: https://prepelephant.com/topics/mbbs/pathology/men-syndromes-pathology - Exam / course: MBBS · Subject: Pathology - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-02 - Last updated: 2026-10-02 - How to cite: "MEN Syndromes Pathology", PrepElephant, https://prepelephant.com/topics/mbbs/pathology/men-syndromes-pathology ## Direct answer Three genes anchor the multiple endocrine neoplasia (MEN) map: MEN1 (menin, chromosome 11q13) producing the "3 Ps" — parathyroid hyperplasia, enteropancreatic neuroendocrine tumours and pituitary adenomas; RET (10q11.2) in MEN2A, adding medullary thyroid carcinoma, pheochromocytoma and parathyroid disease; and the same RET gene at codon 918 in MEN2B, where mucosal neuromas and a marfanoid habitus replace the parathyroid component. All are autosomal dominant, but their management differs radically: MEN1 is a surveillance programme of biochemical screening, while MEN2 is a surgical-prevention programme, because prophylactic thyroidectomy in childhood — timed to the RET codon risk category — removes the medullary carcinoma that is otherwise virtually inevitable. Operate the pheochromocytoma before the thyroid, always, or the catecholamine surge of thyroid surgery kills the patient. ## What you must remember - **MEN1 (Wermer):** primary hyperparathyroidism in over 90 per cent (four-gland hyperplasia), enteropancreatic tumours in roughly 40 to 60 per cent — gastrinoma the commonest functioning tumour (Zollinger-Ellison syndrome), then insulinoma — and pituitary adenomas in about a third, prolactinoma leading; also foregut carcinoids and adrenal tumours. - **MEN1 screening panel:** calcium and parathyroid hormone yearly, plus prolactin, insulin-like growth factor 1, and gastrin or chromogranin A — a quotable annual set, with imaging at intervals; penetrance is near-complete by later life. - **MEN2A (Sipple):** medullary thyroid carcinoma in virtually 100 per cent (bilateral, multifocal, preceded by C-cell hyperplasia), pheochromocytoma in about 50 per cent (bilateral in half), parathyroid hyperplasia in 20 to 30 per cent; cutaneous lichen amyloidosis is a recognised marker. - **MEN2B:** the earliest and most aggressive medullary carcinoma, pheochromocytoma, mucosal neuromas of lips and tongue, marfanoid habitus and gastrointestinal ganglioneuromatosis causing constipation — with no parathyroid disease, the negative that examiners love. - **RET risk categories drive surgery timing (per American Thyroid Association guidance):** MEN2B (codon 918, highest risk) — thyroidectomy within the first year of life; MEN2A codon 634 — by around age five; lower-risk codons later, with calcitonin surveillance. - **Sequencing rule:** in a MEN2 patient with both pheochromocytoma and medullary carcinoma, the adrenal is dealt with first after alpha-blockade, because uncontrolled catecholamine release under thyroid-surgery anaesthesia is lethal. - **Calcitonin as marker:** basal and stimulated calcitonin track C-cell disease; the precursor lesion is diffuse C-cell hyperplasia, more than a specified number of C cells per follicle — histology examiners accept as the definition. ## How cascade screening actually runs Consider a 28-year-old whose father died of metastatic medullary thyroid carcinoma. The index step is RET sequencing of the affected relative or, failing that, of the proband; a codon-634 mutation confirms MEN2A. Every first-degree relative then offers a blood sample, not a calcitonin level — genetic testing precedes biochemical testing because C-cell disease begins before calcitonin rises reliably. A positive nine-year-old cousin undergoes calcitonin measurement and thyroidectomy timed to the risk category; a positive 45-year-old aunt additionally needs annual plasma metanephrines and calcium. Each operated thyroid is examined for C-cell hyperplasia and microcarcinoma, and each patient — even after apparently curative surgery — remains on lifelong calcitonin and carcinoembryonic antigen surveillance for recurrence. MEN1 cascade runs on biochemistry rather than prophylactic surgery: the parathyroids are hyperplastic and recurrent, pancreatic tumours are multiple and often duodenal (gastrinomas in the duodenal submucosa are small and easily missed — a surgical aphorism worth quoting), and pituitary disease is monitored with hormone profiles and imaging. The two syndromes thus teach opposite philosophies: RET is a gene you act on surgically; MEN1 is a gene you watch. ## Where the exam sets its traps Candidates routinely blur the direction of the MEN2A-thyroid relationship: virtually all MEN2A patients develop medullary carcinoma, but only a minority of sporadic medullary carcinomas are heritable — hence RET testing is now offered to every medullary carcinoma patient, not only the familial ones. The second trap is the MEN2B face: the child with mucosal neuromas and constipation from ganglioneuromatosis goes undiagnosed for years; recognising the phenotype at a viva desk is precisely the point. Third, do not transplant MEN1 habits into MEN2: prophylactic pancreatectomy is never done; prophylactic thyroidectomy always is, at the codon-appropriate age. ## Frequently asked questions ### Which three organs define MEN1 and which tumour is commonest? Parathyroids (hyperplasia, over 90 per cent), enteropancreatic neuroendocrine tumours and pituitary adenomas; primary hyperparathyroidism is the commonest and usually first manifestation. ### What distinguishes MEN2B from MEN2A? MEN2B adds mucosal neuromas, marfanoid habitus and gut ganglioneuromatosis, has earlier and more aggressive medullary carcinoma, and lacks parathyroid hyperplasia. ### Why is prophylactic thyroidectomy performed in RET mutation carriers? Medullary carcinoma is virtually inevitable and radioiodine-insensitive, so removing the thyroid at a codon-determined age — in infancy for MEN2B — prevents incurable disease. ### Which tumour is operated first when pheochromocytoma and medullary carcinoma coexist? The pheochromocytoma, after alpha-blockade, so that thyroid surgery is not complicated by an intraoperative catecholamine crisis. ### What is the precursor lesion of medullary thyroid carcinoma in MEN2? Diffuse and nodular C-cell hyperplasia — multifocal bilateral expansion of calcitonin-secreting parafollicular cells preceding invasive carcinoma.